onr:"swepub:oai:lup.lub.lu.se:d9dcc17c-3ff2-4b17-b5ee-ab4e0f0c35fc"
Search: onr:"swepub:oai:lup.lub.lu.se:d9dcc17c-3ff2-4b17-b5ee-ab4e0f0c35fc" > A multi-omic study ...
- 1 of 1
- Previous record
- Next record
- To hitlist
A multi-omic study reveals BTG2 as a reliable prognostic marker for early-stage non-small cell lung cancer
-
- Shen, Sipeng (author)
- Nanjing Medical University,Harvard University
-
- Zhang, Ruyang (author)
- Nanjing Medical University
-
- Guo, Yichen (author)
- Harvard University
- show more...
- show less...
- (creator_code:org_t)
- 2018-05-04
- 2018
- English.
- In: Molecular Oncology. - : Wiley. - 1574-7891 .- 1878-0261. ; 12:6, s. 913-924
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- B-cell translocation gene 2 (BTG2) is a tumour suppressor protein known to be downregulated in several types of cancer. In this study, we investigated a potential role for BTG2 in early-stage non-small cell lung cancer (NSCLC) survival. We analysed BTG2 methylation data from 1230 early-stage NSCLC patients from five international cohorts, as well as gene expression data from 3038 lung cancer cases from multiple cohorts. Three CpG probes (cg01798157, cg06373167, cg23371584) that detected BTG2 hypermethylation in tumour tissues were associated with lower overall survival. The prognostic model based on methylation could distinguish patient survival in the four cohorts [hazard ratio (HR) range, 1.51-2.21] and the independent validation set (HR = 1.85). In the expression analysis, BTG2 expression was positively correlated with survival in each cohort (HR range, 0.28-0.68), which we confirmed with meta-analysis (HR = 0.61, 95% CI 0.54-0.68). The three CpG probes were all negatively correlated with BTG2 expression. Importantly, an integrative model of BTG2 methylation, expression and clinical information showed better predictive ability in the training set and validation set. In conclusion, the methylation and integrated prognostic signatures based on BTG2 are stable and reliable biomarkers for early-stage NSCLC. They may have new applications for appropriate clinical adjuvant trials and personalized treatments in the future.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- BTG2
- Early-stage non-small cell lung cancer
- Multi-omic
- Prognosis
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
- Molecular Oncology (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Shen, Sipeng
- Zhang, Ruyang
- Guo, Yichen
- Loehrer, Elizabe ...
- Wei, Yongyue
- Zhu, Ying
- show more...
- Yuan, Qianyu
- Moran, Sebastian
- Fleischer, Thoma ...
- Bjaanæs, Maria M ...
- Karlsson, Anna
- Planck, Maria
- Staaf, Johan
- Helland, Åslaug
- Esteller, Manel
- Su, Li
- Chen, Feng
- Christiani, Davi ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Molecular Oncolo ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
